NVO Novo Nordisk A/S

NVO's Wegovy pill delivers an average weight loss of 4.1% after three months for adults switching from injectable GLP-1 therapies.

LLY and Novo face off at EASD as new data fuels the GLP-1 market, while ETFs offer diversified exposure to weight loss drug growth.

Novo's real-world study finds that patients who increase their Ozempic to 2 mg have a lower observed MACE risk than those who switch to Mounjaro.

Delcath Systems, Viking Therapeutics and AxoGen show growth potential backed by analyst Moderate Buy ratings and strong institutional ownership, despite risks like dilution and patent cliffs.

AutoZone, Eli Lilly, Meta Platforms, and Costco all trade at high share prices, making them candidates for stock splits as analysts raise price targets and cite strong fundamentals.

A real-world study of 194 patients found those who switched to the daily pill lost an average of 8.8 pounds over 3 months

NVO's latest Hengrui deal adds a phase I-ready, once-weekly oral GLP-1/GIP candidate, building on deals for oral drug-delivery tech and small-molecule approaches.

Novo Nordisk (NVO) concluded the recent trading session at $38.31, signifying a -1.03% move from its prior day's close.

Eli Lilly and Co. revealed new analysis data indicating that its medications, Zepbound and Foundayo, yielded superior weight loss and blood sugar control compared to competing Novo Nordisk A/S semaglutide treatments. The pharmaceutical developer presented these findings at the Annual...

Novo Nordisk (CPSE:NOVO B) entered an exclusive license with Hengrui Pharma for a once-weekly oral GLP-1/GIP dual agonist. Phase 3 CagriSema data delivered new weight management clinical results that add another late-stage asset to Novo Nordisk’s pipeline. The CHMP issued a positive opinion backing Sogroya for idiopathic short stature and supported FREHEMGO for hemophilia A patients. The Hengrui oral GLP-1/GIP deal and new trial wins tell only part of the Novo Nordisk story. We have also...

Zepbound 15 mg was associated with 4.5 percentage points more weight loss than Wegovy HD.

Eli Lilly is growing faster than any other mega-cap drugmaker, but a pipeline drug still awaiting approval and falling U.S. prices are pulling the stock in opposite directions. The outcome of that tension shapes whether shares have another 20% to climb or stall near today's levels.

An indirect comparison favored Foundayo, but no head-to-head trial has established superiority over oral semaglutide.

Novo Nordisk Drops Big Ozempic Finding From 630,000-Patient Study

The Danish drugmaker agreed to pay up to $2.6 billion for rights to Hengrui’s once-weekly oral GLP-1/GIP candidate as it races to rebuild its post-Wegovy pipeline.

NVO and PFE offer different growth paths, with diversified portfolios, pipelines and near-term challenges shaping their outlooks.

Investing.com --Jiangsu Hengrui Pharmaceuticals (HK:1276) shares rose in Hong Kong on Tuesday after Novo Nordisk entered an agreement to license the Chinese drugmaker’s experimental obesity and diabetes treatment in a deal worth up to $2.6 billion.

The Danish drugmaker signed a licensing deal for a weight-loss treatment being developed by Hengrui Pharma that could be worth up to $2.6 billion.

Anthropic’s claim that Claude autonomously discovered a novel enzyme system is reportedly facing scrutiny after a computational biologist questioned the source of the discovery. Mario Rodríguez Mestre said he and his colleagues had been studying the ART enzymes and related...

Citigroup sees a path to 35% gains from here, but Eli Lilly's pricing headwinds, a slow oral GLP-1 launch, and a rival in freefall raise a real question about whether this pause signals opportunity or a longer stall ahead.

Novo has 44 abstracts at EASD, including CagriSema analyses and Phase 2b Zenagamtide results.

A stock that has lost more than 70% of its value from the peak tends to invite hard questions, and Novo Nordisk A/S (NYSE:NVO) is now facing them from its own investors. Late September 2026 brought renewed pressure on the company to explain what comes after its weight-loss drug franchise, as analysts project Eli Lilly’s […]

Bristol Myers Squibb raised its 2026 sales outlook in July, while Novo Nordisk expects its sales to be flat at best this year, yet Bristol Myers Squibb trades at the lower earnings multiple.

Novo Nordisk A/S (NYSE:NVO) has signed a drug-discovery and licensing agreement with Orbis Medicines worth up to $1.4 billion to develop oral therapies for cardiometabolic diseases that are traditionally treated with injections. The deal includes upfront and potential development and commercial milestone payments, tiered royalties on future sales, and a strategic investment by Novo in […]

Novo Nordisk A/S (NYSE:NVO) is defending its push to diversify beyond obesity as CEO Mike Doustdar signals that the company is willing to pursue deals to build growth outside its core weight-loss franchise. At its September 2026 Capital Markets Day, Novo said it aims to launch more than five multi-blockbuster medicines by 2030 and generate […]

Novo Nordisk (CPSE:NOVO B) agreed a €1.165b global licensing deal with Swedish drug delivery specialist Nanexa for long-acting injectables. The collaboration targets obesity, type 2 diabetes, and wider cardiometabolic conditions using Nanexa's PharmaShell depot technology to extend dosing intervals. Novo Nordisk gains exclusive rights to apply PharmaShell across selected pipeline assets, with Nanexa eligible for upfront, milestone, and royalty payments. The Nanexa PharmaShell licensing deal...

Eli Lilly is the leader in the GLP-1 space, but not every new drug the company is working on will be a winner.

Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) were once viewed as the two big winners of the GLP-1 boom. However, the market’s view of the two companies has changed sharply. Since mid-2024, Novo’s stock has fallen roughly 74%, while Lilly’s has gained about 35%. That difference is also reflected in their valuations, […]

Big pharma is still paying up, but more often for delivery and discovery engines than for a single late-stage asset.

European stock markets closed mostly higher in Friday trading as oil prices fell amid hopes of a pos

Eli Lilly gets FDA approval for once-weekly Onswik, offering adults with type II diabetes a more convenient alternative to daily basal insulin.

The collaboration covers up to five programs in obesity, diabetes and other cardiometabolic diseases.

Nanexa's shares more than doubled

The agreement gives Novo exclusive rights to Swedish startup Nanexa's drug-coating technology for up to 5 programs targeting obesity and diabetes

Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

The biotech player could eventually rival big pharma companies.

Novo Nordisk (NYSE:NVO) has agreed to license drug-delivery technology from Swedish biotechnology company Nanexa in an agreement potentially worth up to €1. 165 billion.

↗️ Akamai Technologies (AKAM): An $11.6 billion cloud-services deal with Anthropic sent shares in the company soaring 20% premarket. ↗️ People (PPLI): Barry Diller's company has gone from potential acquirer of MGM Resorts International (MGM) to a possible target for the casino operator, The Wall Street Journal reported.

Novo Nordisk agreed to license and develop the technology, which could cut the frequency patients need to inject its obesity and diabetes drugs.

Investing.com -- Shares of Nanexa surged more than 110% in early Friday trading after the Swedish drug-delivery company announced a global licensing and collaboration agreement with Novo Nordisk worth up to €1.165 billion ($1.3 billion), covering technology aimed at making obesity and diabetes treatments longer-lasting.

CEO Mike Doustdar spoke openly about a risk facing Wegovy and Ozempic, and Wall Street’s growth expectations for Novo shifted quickly.

Novo Nordisk trades at a steep discount on earnings and sales, while AbbVie grapples with patent cliffs and pricing pressure, but profitability tells a different story.

Novo Nordisk (NYSE:NVO) outlined new long term growth ambitions and patent transition plans for semaglutide in a recent investor update. Management detailed how upcoming semaglutide patent expiries could affect diabetes and obesity care revenue concentration across major markets. The company set out pipeline goals aimed at supporting future sales once exclusivity for key semaglutide formulations comes to an end. Novo Nordisk's long term growth and semaglutide patent strategy is important,...

European equities traded in the US as American depositary receipts were tracking slightly lower Thur

Novo Nordisk (NVO) closed the most recent trading day at $38.17, moving 3.12% from the previous trading session.

The U.S. now accounts for more than half of Novo Nordisk’s revenue.

NVO stock is down 11% this week, on track for its worst week since late February if losses hold.

Recent weight gain was associated with a higher likelihood of losing at least 10% of body weight.

Viking Therapeutics shares jumped 36% after VK2735 maintenance data showed patients kept most weight loss on less frequent dosing, though Phase 3 results and commercial funding remain unresolved.

Novo Nordisk (NYSE:NVO) (NYSE:NVO), the Danish drugmaker, would be open to considering a direct listing of its shares on the New York Stock Exchange, according to chief executive Mike Doustdar. Doustdar told the Financial Times that he could see advantages to such a move, although he...